Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
183
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 48 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 5 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| — | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AURO-SUNITINIB (DIN 02532212) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database… | DIN02532212 | approved | health-canada-dpd |
| — | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as OXALIPLATIN INJECTION (DIN 02532131) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product… | DIN02532131 | approved | health-canada-dpd |
| — | Azacitidine | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-AZACITIDINE FOR INJECTION (DIN 02532085) under ATC L01BC07 AZACITIDINE. Indications are not published in the Drug… | DIN02532085 | withdrawnsource: Cancelled Pre Marketsince Jul 31, 2026 | health-canada-dpd |
| — | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYCLOPHOSPHAMIDE FOR INJECTION (DIN 02531046) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in… | DIN02531046 | withdrawnsource: Cancelled Pre Marketsince Jun 9, 2025 | health-canada-dpd |
| — | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYCLOPHOSPHAMIDE FOR INJECTION (DIN 02531038) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in… | DIN02531038 | withdrawnsource: Cancelled Pre Marketsince Jun 9, 2025 | health-canada-dpd |
| — | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYCLOPHOSPHAMIDE FOR INJECTION (DIN 02531011) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published in… | DIN02531011 | withdrawnsource: Cancelled Pre Marketsince Jun 9, 2025 | health-canada-dpd |
| — | Paclitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as PACLITAXEL INJECTION (DIN 02529424) under ATC L01CD01 PACLITAXEL. Indications are not published in the Drug Product… | DIN02529424 | approved | health-canada-dpd |
| — | Carboplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CARBOPLATIN INJECTION (DIN 02528916) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug Product… | DIN02528916 | approved | health-canada-dpd |
| — | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION (DIN 02528797) under ATC L01CE02 IRINOTECAN. Indications are not published in the… | DIN02528797 | approved | health-canada-dpd |
| — | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION (DIN 02528770) under ATC L01CE02 IRINOTECAN. Indications are not published in the… | DIN02528770 | approved | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02528762) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02528762 | approved | health-canada-dpd |
| — | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CAPECITABINE (DIN 02528150) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02528150 | approved | health-canada-dpd |
| — | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as CAPECITABINE (DIN 02528126) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02528126 | approved | health-canada-dpd |
| — | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as ESAMUZE (DIN 02527073) under ATC L01AA09 BENDAMUSTINE. Indications are not published in the Drug Product Database —… | DIN02527073 | approved | health-canada-dpd |
| — | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02526980) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02526980 | approved | health-canada-dpd |
| — | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02526972) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02526972 | approved | health-canada-dpd |
| — | Melphalan | Health Canada CA | cancer not stated in this record | Marketed in Canada as MELPHALAN FOR INJECTION (DIN 02526077) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product… | DIN02526077 | withdrawnsource: Cancelled Pre Marketsince Jul 29, 2026 | health-canada-dpd |
| — | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as ABIRATERONE (DIN 02525372) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product Database… | DIN02525372 | approved | health-canada-dpd |
| — | Sunitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-SUNITINIB (DIN 02524074) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database… | DIN02524074 | approved | health-canada-dpd |
| — | Trabectedin | Health Canada CA | cancer not stated in this record | Marketed in Canada as NAT-TRABECTEDIN (DIN 02523531) under ATC L01CX01 TRABECTEDIN. Indications are not published in the Drug Product… | DIN02523531 | approved | health-canada-dpd |
| — | Leuprolide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CAMCEVI (DIN 02522446) under ATC L02AE02 LEUPRORELIN. Indications are not published in the Drug Product Database —… | DIN02522446 | approved | health-canada-dpd |
| — | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-BORTEZOMIB (DIN 02521814) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug Product… | DIN02521814 | approved | health-canada-dpd |
| — | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ ABIRATERONE (DIN 02521652) under ATC L02BX03 ABIRATERONE. Indications are not published in the Drug Product… | DIN02521652 | approved | health-canada-dpd |
| — | Busulfan | Health Canada CA | cancer not stated in this record | Marketed in Canada as BUSULFAN FOR INJECTION (DIN 02521296) under ATC L01AB01 BUSULFAN. Indications are not published in the Drug Product… | DIN02521296 | approved | health-canada-dpd |
| — | Pazopanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ PAZOPANIB (DIN 02521180) under ATC L01EX03 PAZOPANIB. Indications are not published in the Drug Product… | DIN02521180 | withdrawnsource: Cancelled Pre Marketsince Oct 26, 2023 | health-canada-dpd |
| — | Infigratinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRUSELTIQ (DIN 02520664) under ATC L01EN03 INFIGRATINIB. Indications are not published in the Drug Product Database —… | DIN02520664 | withdrawnsource: Cancelled Pre Marketsince Jan 23, 2023 | health-canada-dpd |
| — | Infigratinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRUSELTIQ (DIN 02520656) under ATC L01EN03 INFIGRATINIB. Indications are not published in the Drug Product Database —… | DIN02520656 | withdrawnsource: Cancelled Pre Marketsince Jan 23, 2023 | health-canada-dpd |
| — | Infigratinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRUSELTIQ (DIN 02520648) under ATC L01EN03 INFIGRATINIB. Indications are not published in the Drug Product Database —… | DIN02520648 | withdrawnsource: Cancelled Pre Marketsince Jan 23, 2023 | health-canada-dpd |
| — | Infigratinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRUSELTIQ (DIN 02520621) under ATC L01EN03 INFIGRATINIB. Indications are not published in the Drug Product Database —… | DIN02520621 | withdrawnsource: Cancelled Pre Marketsince Jan 23, 2023 | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02517655) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02517655 | approved | health-canada-dpd |
| — | Treosulfan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TRECONDYV (DIN 02517361) under ATC L01AB02 TREOSULFAN. Indications are not published in the Drug Product Database —… | DIN02517361 | approved | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP TEMOZOLOMIDE (DIN 02516837) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02516837 | approved | health-canada-dpd |
| — | Idecabtagene Vicleucel | Health Canada CA | cancer not stated in this record | Marketed in Canada as ABECMA (DIN 02516233) under ATC L01XL07 IDECABTAGENE VICLEUCEL. Indications are not published in the Drug Product… | DIN02516233 | withdrawnsource: Cancelled Pre Marketsince Nov 14, 2023 | health-canada-dpd |
| — | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ IMATINIB (DIN 02515555) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database… | DIN02515555 | withdrawnsource: Cancelled Pre Marketsince Oct 25, 2023 | health-canada-dpd |
| — | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SANDOZ IMATINIB (DIN 02515547) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database… | DIN02515547 | withdrawnsource: Cancelled Pre Marketsince Oct 25, 2023 | health-canada-dpd |
| — | Afatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-AFATINIB (DIN 02514613) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database —… | DIN02514613 | withdrawnsource: Cancelled Pre Marketsince Apr 9, 2025 | health-canada-dpd |
| — | Afatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-AFATINIB (DIN 02514605) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database —… | DIN02514605 | withdrawnsource: Cancelled Pre Marketsince Apr 9, 2025 | health-canada-dpd |
| — | Afatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-AFATINIB (DIN 02514591) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database —… | DIN02514591 | withdrawnsource: Cancelled Pre Marketsince Apr 9, 2025 | health-canada-dpd |
| — | Glatiramer | Health Canada CA | cancer not stated in this record | Marketed in Canada as COPAXONE (DIN 02512173) under ATC L03AX13 GLATIRAMER ACETATE. Indications are not published in the Drug Product… | DIN02512173 | approved | health-canada-dpd |
| — | Melphalan | Health Canada CA | cancer not stated in this record | Marketed in Canada as MELPHALAN FOR INJECTION (DIN 02508214) under ATC L01AA03 MELPHALAN. Indications are not published in the Drug Product… | DIN02508214 | approved | health-canada-dpd |
| — | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as MINT-CAPECITABINE (DIN 02508001) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02508001 | approved | health-canada-dpd |
| — | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as PRIVA-LETROZOLE (DIN 02504286) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product… | DIN02504286 | withdrawnsource: Cancelled Pre Marketsince Jul 29, 2022 | health-canada-dpd |
| — | Cabazitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as CABAZITAXEL FOR INJECTION (DIN 02503581) under ATC L01CD04 CABAZITAXEL. Indications are not published in the Drug… | DIN02503581 | approved | health-canada-dpd |
| — | Daunorubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as DAUNORUBICIN INJECTABLE SOLUTION (DIN 02501473) under ATC L01DB02 DAUNORUBICIN. Indications are not published in the… | DIN02501473 | approved | health-canada-dpd |
| — | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION (DIN 02501287) under ATC L01CE02 IRINOTECAN. Indications are not published in the… | DIN02501287 | approved | health-canada-dpd |
| — | Irinotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as IRINOTECAN HYDROCHLORIDE INJECTION (DIN 02501260) under ATC L01CE02 IRINOTECAN. Indications are not published in the… | DIN02501260 | approved | health-canada-dpd |
| — | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB FOR INJECTION (DIN 02497433) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug… | DIN02497433 | approved | health-canada-dpd |
| — | Alpelisib | Health Canada CA | cancer not stated in this record | Marketed in Canada as PIQRAY (DIN 02497042) under ATC L01EM03 ALPELISIB. Indications are not published in the Drug Product Database — see… | DIN02497042 | approved | health-canada-dpd |
| — | Abiraterone Acetate | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-ABIRATERONE ACETATE FILM COATED TABLETS (DIN 02496100) under ATC L02BX03 ABIRATERONE. Indications are not… | DIN02496100 | approved | health-canada-dpd |
| — | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB FOR INJECTION (DIN 02494922) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug… | DIN02494922 | withdrawnsource: Cancelled Pre Marketsince Jul 29, 2026 | health-canada-dpd |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.